Capital Expenditures
The latest quarterly capex is $-27.80 Million with a quarter-over-quarter change of +79.42%. Capital Expenditures (CapEx) represents spending on physical assets like property, plant, equipment, and technology infrastructure. It's the investment in the company's future productive capacity.
PODD CapEx
Reported quarterly capital expenditures; no daily interpolation.
Current CapEx
$-27.80M
$-27.80 Million
Quarter-over-Quarter Change
+79.42%
vs. $-135.10M prior quarter
Historical Data
78
Quarters of data available
Quarterly CapEx History
| Period | CapEx | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $-27.80M | +$107.30M | +79.42% |
| Q4 2025 | $-135.10M | $-114.10M | -543.33% |
| Q3 2025 | $-21.00M | +$2.20M | +9.48% |
| Q2 2025 | $-23.20M | $-10.90M | -88.62% |
| Q1 2025 | $-12.30M | +$43.70M | +78.04% |
| Q4 2024 | $-56.00M | $-29.30M | -109.74% |
| Q3 2024 | $-26.70M | $-4.20M | -18.67% |
| Q2 2024 | $-22.50M | +$1.50M | +6.25% |
| Q1 2024 | $-24.00M | $-26.00M | -1300.00% |
| Q4 2023 | $2.00M | +$24.40M | +108.93% |
| Q3 2023 | $-22.40M | $-4.30M | -23.76% |
| Q2 2023 | $-18.10M | +$19.00M | +51.21% |
| Q1 2023 | $-37.10M | +$51.30M | +58.03% |
| Q4 2022 | $-88.40M | $-54.50M | -160.77% |
| Q3 2022 | $-33.90M | $-14.80M | -77.49% |
| Q2 2022 | $-19.10M | $-3.20M | -20.13% |
| Q1 2022 | $-15.90M | +$21.00M | +56.91% |
| Q4 2021 | $-36.90M | $-7.70M | -26.37% |
| Q3 2021 | $-29.20M | $-6.00M | -25.86% |
| Q2 2021 | $-23.20M | +$10.20M | +30.54% |
| Q1 2021 | $-33.40M | +$36.30M | +52.08% |
| Q4 2020 | $-69.70M | $-43.20M | -163.02% |
| Q3 2020 | $-26.50M | $-1.70M | -6.85% |
| Q2 2020 | $-24.80M | +$2.60M | +9.49% |
| Q1 2020 | $-27.40M | +$22.52M | +45.12% |
| Q4 2019 | $-49.92M | $-27.23M | -119.93% |
| Q3 2019 | $-22.70M | +$28.96M | +56.06% |
| Q2 2019 | $-51.66M | $-6.40M | -14.15% |
| Q1 2019 | $-45.26M | $-10.46M | -30.06% |
| Q4 2018 | $-34.80M | +$2.83M | +7.51% |
| Q3 2018 | $-37.62M | +$16.94M | +31.05% |
| Q2 2018 | $-54.56M | $-19.19M | -54.25% |
| Q1 2018 | $-35.37M | $-5.96M | -20.27% |
| Q4 2017 | $-29.41M | $-20.67M | -236.34% |
| Q3 2017 | $-8.74M | +$4.64M | +34.69% |
| Q2 2017 | $-13.39M | +$12.29M | +47.86% |
| Q1 2017 | $-25.68M | $-22.77M | -782.44% |
| Q4 2016 | $-2.91M | +$10.39M | +78.12% |
| Q3 2016 | $-13.30M | $-10.55M | -384.52% |
| Q2 2016 | $-2.75M | +$415,000 | +13.13% |
| Q1 2016 | $-3.16M | +$322,000 | +9.25% |
| Q4 2015 | $-3.48M | $-957,000 | -37.90% |
| Q3 2015 | $-2.52M | $-2.27M | -890.20% |
| Q2 2015 | $-255,000 | +$4.09M | +94.13% |
| Q1 2015 | $-4.35M | $-1.71M | -65.06% |
| Q4 2014 | $-2.63M | +$475,000 | +15.28% |
| Q3 2014 | $-3.11M | +$480,000 | +13.38% |
| Q2 2014 | $-3.59M | $-1.43M | -66.34% |
| Q1 2014 | $-2.16M | +$633,000 | +22.69% |
| Q4 2013 | $-2.79M | $-968,000 | -53.13% |
| Q3 2013 | $-1.82M | $-196,000 | -12.05% |
| Q2 2013 | $-1.63M | $-557,000 | -52.10% |
| Q1 2013 | $-1.07M | +$986,000 | +47.98% |
| Q4 2012 | $-2.06M | +$2.63M | +56.16% |
| Q3 2012 | $-4.69M | $-2.14M | -83.80% |
| Q2 2012 | $-2.55M | $-851,000 | -50.09% |
| Q1 2012 | $-1.70M | +$577,000 | +25.35% |
| Q4 2011 | $-2.28M | +$1.00M | +30.57% |
| Q3 2011 | $-3.28M | $-615,000 | -23.09% |
| Q2 2011 | $-2.66M | +$234,000 | +8.08% |
| Q1 2011 | $-2.90M | +$20,000 | +0.69% |
| Q4 2010 | $-2.92M | $-1.27M | -77.22% |
| Q3 2010 | $-1.65M | $-750,000 | -83.71% |
| Q2 2010 | $-896,000 | +$194,000 | +17.80% |
| Q1 2010 | $-1.09M | +$82,000 | +7.00% |
| Q4 2009 | $-1.17M | +$40,000 | +3.30% |
| Q3 2009 | $-1.21M | $-621,000 | -105.08% |
| Q2 2009 | $-591,000 | $-426,000 | -258.18% |
| Q1 2009 | $-165,000 | +$441,000 | +72.77% |
| Q4 2008 | $-606,000 | +$1.01M | +62.52% |
| Q3 2008 | $-1.62M | +$928,000 | +36.46% |
| Q2 2008 | $-2.54M | +$2.73M | +51.79% |
| Q1 2008 | $-5.28M | $-3.53M | -201.83% |
| Q4 2007 | $-1.75M | +$1.08M | +38.20% |
| Q3 2007 | $-2.83M | +$349,000 | +10.98% |
| Q2 2007 | $-3.18M | $-848,000 | -36.38% |
| Q1 2007 | $-2.33M | $-1,000 | -0.04% |
| Q4 2006 | $-2.33M | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy